| Literature DB >> 28011619 |
Xiaoyan Sun1,2, Weiguang Wang3, Jiao Chen1,2, Xueting Cai1,2, Jie Yang1,2, Yang Yang1,2, Huaijiang Yan1,2, Xiaolan Cheng1,2, Juan Ye1,2, Wuguang Lu1,2, Chunping Hu1,2, Handong Sun3, Jianxin Pu4, Peng Cao5,2.
Abstract
Aberrant expression of thioredoxin 1 (Trx1) plays an important role in cancer initiation and progression and has gained attention as an anticancer drug target. Here we report that the recently discovered natural diterpenoid isoforretin A (IsoA) significantly inhibits Trx1 activity and mediates anticancer effects in multiple preclinical settings. The inhibitory effect of IsoA was antagonized by free radical scavengers polyethylene glycol-catalase, polyethylene glycol superoxide dismutase, thiol-based antioxidants N-acetylcysteine and glutathione. Mass spectrometry analysis revealed that the mechanism of action was based on direct conjugation of IsoA to the Cys32/Cys35 residues of Trx1. This conjugation event attenuated reversible thiol reduction of Trx1, leading to ROS accumulation and a broader degradation of thiol redox homeostasis in cancer cells. Extending these in vitro findings, we documented that IsoA administration inhibited the growth of HepG2 tumors in a murine xenograft model of hepatocellular carcinoma. Taken together, our findings highlight IsoA as a potent bioactive inhibitor of Trx1 and a candidate anticancer natural product. Cancer Res; 77(4); 926-36. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 28011619 DOI: 10.1158/0008-5472.CAN-16-0987
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701